Associations of HDL Subspecies Defined by ApoC3 with Non-Alcoholic Fatty Liver Disease: The Multi-Ethnic Study of Atherosclerosis
Open Access
- 31 October 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11), 3522
- https://doi.org/10.3390/jcm9113522
Abstract
Previously, we reported that inverse associations of high-density lipoprotein (HDL) with cardiovascular disease and diabetes were only observed for HDL that lacked the pro-inflammatory protein apolipoprotein C3 (apoC3). To provide further insight into the cardiometabolic properties of HDL subspecies defined by the presence or absence of apoC3, we aimed to examine these subspecies with liver fat content and non-alcoholic fatty liver disease (NAFLD). We investigated cross-sectional associations between ELISA-measured plasma levels of apoA1 in HDL that contained or lacked apoC3 and computed tomography-determined liver fat content and NAFLD (14 drinks/week in men and >7 drinks/week in women). In multivariable-adjusted regression models, apoA1 in HDL that contained or lacked apoC3 was differentially associated with liver fat content (Pheterogeneity = 0.048). While apoA1 in HDL that lacked apoC3 was inversely associated with liver fat content (Ptrend < 0.0001), apoA1 in HDL that contained apoC3 was not statistically significantly associated with liver fat content (Ptrend = 0.57). Higher apoA1 in HDL that lacked apoC3 was related to a lower prevalence of NAFLD (OR per SD: 0.80; 95% CI: 0.72, 0.89), whereas no association was found for apoA1 in HDL that contained apoC3 (OR per SD: 0.95; 95% CI: 0.85, 1.05; Pheterogeneity = 0.09). Higher apoA1 in HDL that lacked apoC3 was associated with less liver fat content and a lower prevalence of NAFLD. This finding extends the inverse association of HDL lacking apoC3 from cardiovascular disease to NAFLD. Lack of biopsy-proven hepatic steatosis and fibrosis data requires the replication of our study in further studies.This publication has 34 references indexed in Scilit:
- Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of AtherosclerosisDiabetologia, 2019
- Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) SubspeciesArteriosclerosis, Thrombosis, and Vascular Biology, 2018
- Apolipoprotein C-III in triglyceride-rich lipoprotein metabolismCurrent Opinion in Lipidology, 2018
- High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four CohortsCirculation, 2018
- High‐Density Lipoprotein Subspecies Defined by Apolipoprotein C‐III and Subclinical Atherosclerosis Measures: MESA (The Multi‐Ethnic Study of Atherosclerosis)Journal of the American Heart Association, 2018
- The epidemiology of non‐alcoholic fatty liver diseaseLiver International, 2017
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesJournal of Hepatology, 2015
- Antisense Inhibition of Apolipoprotein C-III in Patients with HypertriglyceridemiaThe New England Journal of Medicine, 2015
- Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyondJournal of Lipid Research, 2013
- Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver DiseaseThe New England Journal of Medicine, 2010